THE CAMPAIGN FOR SUSTAINABLE RX PRICING

Lobbying client. Federal LDA filings.

Connected on the graph

Inbound (24)

date	from	type	amount	source
—	Dean Rosen	lobbied_for	—	lda_lobbyist_client
—	Annie Wolf	lobbied_for	—	lda_lobbyist_client
—	Jon Adame	lobbied_for	—	lda_lobbyist_client
—	Earl Scott Flood	lobbied_for	—	lda_lobbyist_client
—	Lisa Goldman	lobbied_for	—	lda_lobbyist_client
—	David R Thomas	lobbied_for	—	lda_lobbyist_client
—	Lauren Aronson	lobbied_for	—	lda_lobbyist_client
—	Rosemary Gutierrez	lobbied_for	—	lda_lobbyist_client
—	Sage Eastman	lobbied_for	—	lda_lobbyist_client
—	Stephen M. Cote	lobbied_for	—	lda_lobbyist_client
—	Paul Thornell	lobbied_for	—	lda_lobbyist_client
—	Joseph Edward Brown Iii	lobbied_for	—	lda_lobbyist_client
—	Caitlin Van Sant	lobbied_for	—	lda_lobbyist_client
—	Nichole Distefano	lobbied_for	—	lda_lobbyist_client
—	Alyene Mlinar	lobbied_for	—	lda_lobbyist_client
—	Michael Robinson	lobbied_for	—	lda_lobbyist_client
—	Helen Tolar	lobbied_for	—	lda_lobbyist_client
—	Zachary Mallove	lobbied_for	—	lda_lobbyist_client
—	Elise Finley Pickering	lobbied_for	—	lda_lobbyist_client
—	Erica Jay Chabot	lobbied_for	—	lda_lobbyist_client
—	Bruce Mehlman	lobbied_for	—	lda_lobbyist_client
—	Naveen Parmar	lobbied_for	—	lda_lobbyist_client
—	Alexander Perkins	lobbied_for	—	lda_lobbyist_client
2026-01-01	MEHLMAN CONSULTING, INC.	lobbies_for	$90,000	lda_filing

Outbound (25)

date	type	to	amount	role	source
2026-01-01	lobbies_on_bill	HR 1262 — Mikaela Naylon Give Kids a Chance Act	—	H.R.1262	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 1843 — To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug	—	H.R. 1843	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 3010 — No Handouts for Drug Advertisements Act	—	H.R. 3010	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 3152 — Patent Eligibility Restoration Act of 2025	—	H.R. 3152	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 3160 — PREVAIL Act	—	H.R. 3160	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 3269 — ETHIC Act	—	H.R. 3269	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 3789 — DTC Act of 2025	—	H.R. 3789	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 4570 — Interagency Patent Coordination and Improvement Act of 2025	—	H.R. 4570	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 5526 — Biosimilar Red Tape Elimination Act	—	H.R. 5526	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 6485 — Skinny Labels, Big Savings Act	—	H.R. 6485	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1032 — Major Richard Star Act	—	S. 1032	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1040 — Drug Competition Enhancement Act	—	S.1040	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1041 — Affordable Prescriptions for Patients Act	—	S.1041	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1095 — Stop STALLING Act	—	S. 1095	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1096 — Preserve Access to Affordable Generics and Biosimilars Act	—	S.1096	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1097 — Interagency Patent Coordination and Improvement Act of 2025	—	S. 1097	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1414 — Expedited Access to Biosimilars Act	—	S. 1414	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1546 — Patent Eligibility Restoration Act of 2025	—	S. 1546	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1785 — No Handouts for Drug Advertisements Act	—	S. 1785	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1954 — Biosimilar Red Tape Elimination Act	—	S. 1954	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 2276 — ETHIC Act	—	S. 2276	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 229 — DTC Act of 2025	—	S. 229	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 2630 — Saving NSF’s Workforce Act	—	S. 2630	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 3014 — Ensuring Timely Access to Generics Act of 2025	—	S. 3014	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 43 — Skinny Labels, Big Savings Act	—	S. 43	lobbying_bill_mention

Source id: 175642
General description: A coalition of organizations working on market-based solutions to drug pricing.
State: DC
Country: US
Principal place of business: US
Government-entity client: false
Effective date: 2016-07-12
Total spend (across 1 ingested filings): $90,000

Filings

Posted	Type	Year	Lobbying firm	Income
2026-04-17	`Q1`	2026	MEHLMAN CONSULTING, INC.	$90,000

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.